ES2185378T3 - Quimioterapia de cancer con acetildinalina en combinacion con gemcitabina, capecitabina o cisplatina. - Google Patents

Quimioterapia de cancer con acetildinalina en combinacion con gemcitabina, capecitabina o cisplatina.

Info

Publication number
ES2185378T3
ES2185378T3 ES99935442T ES99935442T ES2185378T3 ES 2185378 T3 ES2185378 T3 ES 2185378T3 ES 99935442 T ES99935442 T ES 99935442T ES 99935442 T ES99935442 T ES 99935442T ES 2185378 T3 ES2185378 T3 ES 2185378T3
Authority
ES
Spain
Prior art keywords
gemcitabine
cisplatin
combination
acetildinaline
capecitabin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99935442T
Other languages
English (en)
Inventor
William Richard Grove
Wayne Daniel Klohs
Ronald Lynn Merriman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2185378T3 publication Critical patent/ES2185378T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Combinación de agentes antineoplásticos que incluyen una cantidad antitumoral de acetildinalina y una cantidad antitumoral de gemcitabina, una sal derivada farmacéuticamente aceptable, capecitabina, o cisplatina.
ES99935442T 1998-09-25 1999-07-08 Quimioterapia de cancer con acetildinalina en combinacion con gemcitabina, capecitabina o cisplatina. Expired - Lifetime ES2185378T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25

Publications (1)

Publication Number Publication Date
ES2185378T3 true ES2185378T3 (es) 2003-04-16

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99935442T Expired - Lifetime ES2185378T3 (es) 1998-09-25 1999-07-08 Quimioterapia de cancer con acetildinalina en combinacion con gemcitabina, capecitabina o cisplatina.

Country Status (34)

Country Link
US (3) US6469058B1 (es)
EP (1) EP1115391B1 (es)
JP (1) JP2002525320A (es)
KR (1) KR20010075348A (es)
CN (1) CN1319009A (es)
AP (1) AP2001002109A0 (es)
AT (1) ATE225655T1 (es)
AU (1) AU762079B2 (es)
BG (1) BG105470A (es)
BR (1) BR9913952A (es)
CA (1) CA2342981A1 (es)
CZ (1) CZ2001905A3 (es)
DE (1) DE69903458T2 (es)
DK (1) DK1115391T3 (es)
EA (1) EA200100369A1 (es)
EE (1) EE200100187A (es)
ES (1) ES2185378T3 (es)
GE (1) GEP20043199B (es)
HK (1) HK1040190A1 (es)
HR (1) HRP20010225B1 (es)
HU (1) HUP0103640A3 (es)
ID (1) ID30046A (es)
IL (1) IL141951A0 (es)
IS (1) IS5888A (es)
NO (1) NO20011493L (es)
NZ (1) NZ510504A (es)
OA (1) OA11659A (es)
PL (1) PL348673A1 (es)
PT (1) PT1115391E (es)
SK (1) SK3602001A3 (es)
TR (1) TR200100859T2 (es)
WO (1) WO2000018393A1 (es)
YU (1) YU22401A (es)
ZA (1) ZA200102233B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010075348A (ko) * 1998-09-25 2001-08-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 아세틸디날린과 겜시타빈, 카페시타빈 또는 시스플라틴을함께 사용하는 항암 화학요법
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
RU2320331C2 (ru) * 2002-03-04 2008-03-27 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС. Способ индукции конечной дифференцировки
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20040018968A1 (en) * 2002-04-15 2004-01-29 George Sgouros Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
WO2004045617A1 (en) * 2002-11-15 2004-06-03 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
US20060165744A1 (en) * 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
US7839972B2 (en) 2005-07-22 2010-11-23 Tomotherapy Incorporated System and method of evaluating dose delivered by a radiation therapy system
ATE507879T1 (de) 2005-07-22 2011-05-15 Tomotherapy Inc System zur verabreichung einer strahlentherapie auf ein sich bewegendes zielgebiet
WO2007014106A2 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of delivering radiation therapy to a moving region of interest
EP1907981A4 (en) * 2005-07-22 2009-10-21 Tomotherapy Inc METHOD AND SYSTEM FOR DOSE EVALUATION ADMINISTERED
JP2009502255A (ja) * 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 治療プランのデリバリにおける品質保証基準を評価するための方法およびシステム
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
KR20080044250A (ko) 2005-07-23 2008-05-20 토모테라피 인코포레이티드 갠트리 및 진료대의 조합된 움직임을 이용하는 방사선치료의 영상화 및 시행
DK2059254T3 (en) 2006-08-31 2015-07-13 Spectrum Pharmaceuticals Inc Sensitization of tumor cells to radiation therapy by administration of endothelin agonists
WO2009096245A1 (ja) * 2008-01-28 2009-08-06 Nanocarrier Co., Ltd. 医薬組成物又は組合せ剤
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
US8324180B2 (en) 2009-04-06 2012-12-04 Eisai Inc. Compositions and methods for treating cancer
US8729130B2 (en) 2011-07-01 2014-05-20 The Broad Institute, Inc. Methods of using novel solid forms of tacedinaline
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
US9443633B2 (en) 2013-02-26 2016-09-13 Accuray Incorporated Electromagnetically actuated multi-leaf collimator
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
AU6878198A (en) 1997-04-24 1998-11-13 Warner-Lambert Company Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
KR20010075348A (ko) * 1998-09-25 2001-08-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 아세틸디날린과 겜시타빈, 카페시타빈 또는 시스플라틴을함께 사용하는 항암 화학요법

Also Published As

Publication number Publication date
AP2001002109A0 (en) 2001-03-31
TR200100859T2 (tr) 2001-08-21
HRP20010225B1 (en) 2004-10-31
WO2000018393A1 (en) 2000-04-06
PL348673A1 (en) 2002-06-03
ATE225655T1 (de) 2002-10-15
EP1115391B1 (en) 2002-10-09
US20030086965A1 (en) 2003-05-08
NO20011493D0 (no) 2001-03-23
BR9913952A (pt) 2001-06-12
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
HUP0103640A2 (en) 2002-06-29
CA2342981A1 (en) 2000-04-06
AU5092199A (en) 2000-04-17
EA200100369A1 (ru) 2001-10-22
DK1115391T3 (da) 2003-02-10
HRP20010225A2 (en) 2002-04-30
ZA200102233B (en) 2002-06-18
DE69903458T2 (de) 2003-07-10
HK1040190A1 (zh) 2002-05-31
BG105470A (en) 2001-12-29
AU762079B2 (en) 2003-06-19
CN1319009A (zh) 2001-10-24
SK3602001A3 (en) 2002-07-02
OA11659A (en) 2004-12-08
CZ2001905A3 (cs) 2001-08-15
JP2002525320A (ja) 2002-08-13
NO20011493L (no) 2001-05-23
IS5888A (is) 2001-03-14
US6469058B1 (en) 2002-10-22
DE69903458D1 (de) 2002-11-14
EE200100187A (et) 2002-08-15
GEP20043199B (en) 2004-03-25
YU22401A (sh) 2004-03-12
PT1115391E (pt) 2003-02-28
EP1115391A1 (en) 2001-07-18
US20030170300A1 (en) 2003-09-11
NZ510504A (en) 2003-09-26
KR20010075348A (ko) 2001-08-09
ID30046A (id) 2001-11-01

Similar Documents

Publication Publication Date Title
ES2185378T3 (es) Quimioterapia de cancer con acetildinalina en combinacion con gemcitabina, capecitabina o cisplatina.
AU7776891A (en) 5-benzyl barbiturate derivatives
BR0207378A (pt) Tratamento de câncer
DK0572437T3 (da) 2,4-diaminoquinazolinderivater til forøgelse af antitumorvirkning
NZ508249A (en) Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
ES2160579T3 (es) Tratamiento de la toxicidad de un agente quimioterapeutico y un agente antivirico con nucleosidos de pirimidina acilados.
MY133016A (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
NO933722D0 (no) Pyrimidin-derivater for forbedring av antitumor-aktivitet
HK1054258B (zh) 旋轉門
WO2001034131A3 (en) Combination chemotherapy
ATE413397T1 (de) Heterosubstituierte c7-taxanacetate als antitumormittel
HUP0402401A2 (hu) Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
NO20014757L (no) C(7)-karbamoyloksysubstituerte taxaner som antitumormidler
SI1115391T1 (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
WO2000016753A3 (de) Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika
PT1135161E (pt) Composicao e metodo terapeutico
AR005417A1 (es) Una composicion farmaceutica antitumoral sinergistica
MX9709749A (es) Metodo para reducir la toxicidad de agentes quimioterapeuticos y antivirales con nucleosidos de pirimidina acilados.